AI assistant
Krystal Biotech, Inc. — Director's Dealing 2022
Nov 29, 2022
31006_dirs_2022-11-28_3508062e-28d9-4f9b-9a06-48ee5f457582.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2022-11-23
Reporting Person: Krishnan Krish S (Director, President and CEO, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-11-23 | Common Stock | S | 4 | $80.01 | Disposed | 1787718 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1726440 | Indirect |
| Common Stock | 90000 | Indirect |
| Common Stock | 50000 | Indirect |
Footnotes
F1: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share.
F2: Directly beneficially owned by Suma S. Krishnan, the spouse of the Reporting Person.
F3: Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.